Related Experiment Video
Updated: Jan 8, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
16.4K
CD58 reshapes the immunosuppressive microenvironment in gliomas through PD-L1 upregulation
Siqi Gou1, Pengfei Zhao2, Lei Zong3
1Department of Pathology, Xi'an No. 3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, Shaanxi, China.
Frontiers in Oncology
|December 24, 2025
Summary
Cluster of Differentiation 58 (CD58) promotes glioma progression by increasing PD-L1 and creating an immunosuppressive tumor microenvironment. Targeting the CD58-PD-L1 pathway may improve glioma immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cluster of Differentiation 58 (CD58) is an immune regulator involved in tumor immune evasion.
- Its precise role in glioma's immunosuppressive microenvironment and programmed death-ligand 1 (PD-L1) regulation is not fully understood.
Purpose of the Study:
- To investigate the clinical and mechanistic significance of CD58 in gliomas.
- To determine if CD58 influences the tumor microenvironment and PD-L1 expression in gliomas.
Main Methods:
- Integrated bioinformatics analysis of TCGA and CGGA datasets.
- In vitro studies involving CD58 knockdown in glioma cell lines (U87MG, LN229).
- Assessed CD58 expression, immune cell infiltration, PD-L1 levels, and cytokine secretion (CCL5, CXCL9, CXCL10).
Main Results:
- CD58 expression is elevated in high-grade gliomas and correlates with clinical indicators.
- CD58 knockdown inhibited glioma cell proliferation, migration, and invasion.
- Silencing CD58 reduced PD-L1 and Vimentin, upregulated ICAM-1, and increased chemokine secretion.
Conclusions:
- CD58 promotes glioma progression via PD-L1 upregulation and immunosuppressive microenvironment.
- CD58 is a potential prognostic biomarker and therapeutic target for gliomas.
- Targeting the CD58-PD-L1 axis could enhance glioma immunotherapy efficacy.
